Information  X 
Enter a valid email address

Hikma Pharmaceutical (HIK)

  Print      Mail a friend       Annual reports

Tuesday 02 March, 2021

Hikma Pharmaceutical

Director/PDMR Shareholding

RNS Number : 9221Q
Hikma Pharmaceuticals Plc
02 March 2021
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Douglas Hurt

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Market purchase of 1,500 Ordinary Shares by Gillian Hurt, spouse of Douglas Hurt

c)

Price(s) and volume(s)

Price(s): £22.65

Volume(s): 1,500

d)

Aggregated information

Volume

Price 

Total

 

 

 1,500

£22.65

£33,975

e)

Date of the transaction

2 March 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760

2 March 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBLGDXXSGDGBD

a d v e r t i s e m e n t